KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Debt (2019 - 2025)

Historic Total Debt for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $9.0 billion.

  • Royalty Pharma's Total Debt rose 1758.3% to $9.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.0 billion, marking a year-over-year increase of 1758.3%. This contributed to the annual value of $9.0 billion for FY2025, which is 1758.3% up from last year.
  • Latest data reveals that Royalty Pharma reported Total Debt of $9.0 billion as of Q4 2025, which was up 1758.3% from $8.9 billion recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Total Debt peaked at $9.0 billion during Q4 2025, and registered a low of $5.9 billion during Q1 2021.
  • Its 5-year average for Total Debt is $7.2 billion, with a median of $7.2 billion in 2021.
  • The largest annual percentage gain for Royalty Pharma's Total Debt in the last 5 years was 2407.66% (2024), contrasted with its biggest fall of 1378.96% (2024).
  • Over the past 5 years, Royalty Pharma's Total Debt (Quarter) stood at $7.2 billion in 2021, then fell by 1.22% to $7.1 billion in 2022, then fell by 13.79% to $6.1 billion in 2023, then rose by 24.08% to $7.6 billion in 2024, then increased by 17.58% to $9.0 billion in 2025.
  • Its last three reported values are $9.0 billion in Q4 2025, $8.9 billion for Q3 2025, and $8.0 billion during Q2 2025.